# TNG260

Source: https://onco.cc/drugs/tng260/  
OnCo record `tng260` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TNG260 is a small-molecule inhibitor from Tango Therapeutics, Inc., in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.

## Summary

TNG260 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Tango Therapeutics, Inc., in non-small-cell lung cancer, small-cell lung cancer. Described in the registry record as a corest inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: TNG260
- Modality: Small-molecule inhibitor
- Mechanism: Described in the registry record as a corest inhibitor; the trial entries below carry the sponsor's wording.

## Sources

- ClinicalTrials.gov: trials of TNG260: https://clinicaltrials.gov/search?intr=TNG260

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- companies: [Tango Therapeutics](https://onco.cc/companies/tango-therapeutics/)
- trials: [Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors](https://onco.cc/trials/nct05887492/)

---
JSON: https://onco.cc/api/v1/entities/tng260.json